Enfuvirtide: Antiretroviral class 4, drug 1

HIV Clinical Trials

Volumn 5, Issue 1, 2004, Pages 1-6

  Asboe, David ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Enfuvirtide; Fusion inhibitors; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; ENFUVIRTIDE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; LICENCE; PAIN; PATIENT COMPLIANCE; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SKIN CYST; SKIN INDURATION; SKIN NODULE;

DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRAL FUSION PROTEINS;

EID: 1642276292     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/RCE8-HADB-EFH8-563X     Document Type: Article

References (31)

1. Gallaher WR, Ball JM, Garry RF, et al. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Human Retroviruses. 1989;5:431-440.
2. Weissenhorn W, Dessen A, Harrison SC, et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997;387:426-430.
3. Furuta RA, Wild CT, Weng Y, et al. Capture of an early fusion-active confrmation of HIV-1 gp-41. Nat Structural Biol. 1998;5:276-279.
4. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses. 1993;9:1051-1053.
5. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41 mediated virus entry. Nat Med 1998;4:1302-1307.
6. Kilby JM, Lalezari JP, Eron J, et al. The safety, plasma pharmacokinetics and antiviral activity of subcutaneous T-20, a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses. 2002;18:685-694.
7. Lalezari JP, DeJesus E, Northfelt D, et al. A controlled phase II trial assessing three doses of enfuvirtide (T20) in combination with abacavir, amprenavir, ritonavir, and efavirenz in non-nucleoside reverse transcriptase inhibitor-naïve HIV-infected adults. Antiviral Ther. In press.
8. Wheat LJ, Lalezari J, Kilby M, at al. A week 48 assessment of high strength T-20 formulations in multi-class experience patients. In: Program and abstracts of Ninth Conference on Retroviruses and Opportunistic Infections; 2002; Seattle, Washington. Abstract 417.
9. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1 infected patients. J Clin Virol. 2003;28(2):217-222.
10. Zhang X, Patel I, Lalezari J, et al. Assessment of metabolic inhibition potential of enfuvirtide using a 5-drug cocktail in HIV-1 infected patients. Poster presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 2003; Washington DC. Poster PIII-73.
11. Boyd M, Ruxrungtham K, Zhang X, Bellibas E, Buss NE, Patel IH. Enfuvirtide investigations on the drug interaction potential in HIV infected patients. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, Massachusetts. Abstract 541.
12. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003:17(5):691-698.
13. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175-2185.
14. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348(22):2186-2195.
15. Katlama C, Arasteh K, Clotet B, et al. Enfuvirtide TORO studies: 48-week results confirm 24-week findings. In: Program and abstracts of the Second IAS Conference on HIV Pathogenesis and Treatment; 2003; Paris. Abstract LB2.
16. Battegay M, DeMasi R, Delehanty J, Chung J, Huson L, Salgo M. Analysis of virological failure through 24 weeks of treatment in the TORO 1 and TORO 2 studies. In: Program and abstracts of the Second IAS Conference on HIV Pathogenesis and Treatment; 2003; Paris. Abstract 574.
17. Ball RA, Kinchelow T. Pathology of injection site reactions with enfuvirtide. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, Massachusetts. Abstract 714.
18. Rimsky LT, Shugars DC, Matthews TJ. Determinants of Human Immunodeficiency Virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998;72(2):986-993.
19. Sista P, Melby T, Greenberg S, at al. Characterizations of baseline and treatment emergent resistance to T-20 observed in phase II clinical trials. In: Program and abstracts of the 11th International HIV Drug Resistance Workshop; July 2002; Seville, Spain. Abstract 21.
20. Mink M, Greenberg ML, Mosier S, at al. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T20 in vitro: Analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site directed mutants in NL4-3. In: Program and abstracts of the 11th International HIV Drug Resistance Workshop; July 2002; Seville, Spain. Abstract 22.
21. Greenberg ML, Melby T, Sista P, at al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, Massachusetts. Abstract 141.
22. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of Human Immunodeficiency Virus type 1 to the fusion inhibitor T20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2001;75:8605-8614.
23. Greenberg ML, McDanal CB, Stanfield-Oakley SA, at al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. In: Program and abstracts from the Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago, Illinois. Abstract 473.
24. Zollner B, Feucht HH, Schroter M, Schafer P, Plettenberg A, Stoehr A, Laufs R. Primary genotypic resistance of HIV-1 to the fusion inhibitors T-20 in long term infected patient. AIDS. 2001;15:935-937.
25. Villahermosa ML, Perez-Alvarez L, Carmona R, at al. Primary resistance mutations to fusion inhibitors and polymorphisms in gp 41 sequences of HIV-1 non-B subtypes and recombinants. AIDS. 2003;17:1083-1104.
26. Roman F, Gonzalez D, Lambert C, et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. JAIDS. 2003;33(2):134-139.
27. Sista P, Melba T, Dhingra U, at al. The fusion inhibitors T-20 and T-1249 demonstrate potent in-vitro antiviral activity against B clade HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades. Antiviral Ther. 2001;6:8.
28. Green J, Wintfield N. Patient acceptance with self-injection of enfuvirtide for HIV over 24 weeks of treatment. In: Program and abstracts of the Sixth International Congress on Drug Therapy in HIV Infection; 2002; Glasgow. Abstract P48.
29. Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patient satisfaction and impact on activities of daily living. AIDS Patient Care STDs. 2002;16:327-335.
30. Church J, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus-1-infected children. Paed Infect Dis J. 2002;21:653-659.
31. Zhang X, Nieforth K, Lang JM, at al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin Pharm Ther. 2002;72:10-19.